Strativa Pharmaceuticals has announced that it has received FDA approval for its disposable single-dose device version of Nascobal cyanocobalamin nasal spray for the treatment of pernicious anemia and other vitamin B12 deficiencies. The new product will be available in September 2014 and will replace the current multi-dose product.
Strativa Senior VP Brand Sales and Marketing Rick Painter said, “Unlike the current device, our new Nascobal single-use device does not require priming, which eliminates product loss. In addition, it permits patients to conveniently receive their dose with one spray per disposable device. Strativa remains committed to improving the product experience of the patients who rely upon us.”
Read the Strativa press release.
